1622206-01-2

Upstream product

• 1622205-97-3 C₁₆H₁₅N₃O₃ 
• 245056-66-0 N-(4-chloropyridin-2-yl)acetamide 
• 19798-80-2 2-Amino-4-chloropyridine 
• 1622205-26-8 4-((6-methoxy-1H-indol-5-yl)oxy)pyridin-2-amine 
• 2380-83-8 5-hydroxy-6-methoxy indole 
• 98258-75-4 (E)-1-(benzyloxy)-2-methoxy-4-nitro-5-(2-nitrovinyl)benzene 
• 63909-29-5 (E)-2-(benzyloxy)-1-methoxy-4-(2-nitrovinyl)benzene 
• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 

Downstream Products

• 1622204-08-3 5-((2-(4-((4-hydroxypiperidin-1-yl)methyl)benzamide)pyridin-4-yl)oxy)-6-methoxy-N-methyl-1H-indole-1-carboxamide 
• 1622204-09-4 5-((2-(4-(((3S,4S)-3-hydroxy-4-methoxypyrrolidin-1-yl)methyl)benzamide)pyridin-4-yl)oxy)-6-methoxy-N-methyl-1,4-indole-1-carboxamide 

Relevant academic research and scientific papers

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.